Zimmer Partners’s Ascendis Pharma A/S ASND Stock Holding History

Zimmer Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,500	Closed	-$3.08M	–	126
2025 Q3	$3.08M	Sell	15,500 -24,800	-62%	-$4.63M	0.07%	117
2025 Q2	$6.96M	Buy	40,300 +4,200	+12%	+$684K	0.15%	96
2025 Q1	$5.63M	Sell	36,100 -60,800	-63%	-$8.68M	0.11%	110
2024 Q4	$13.3M	Buy	96,900 +18,900	+24%	+$2.48M	0.23%	65
2024 Q3	$11.6M	Buy	+78,000	New	+$10.5M	0.21%	76

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Zimmer Partners's ASND Position: Q4 2025 in Review

Zimmer Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 15,500 shares — an estimated $3.08M sold.

Zimmer Partners first reported a position in ASND in Q3 2024 and held it in 5 quarters. The position peaked at $13.3M in Q4 2024. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Zimmer Partners reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Zimmer Partners sold 15,500 Ascendis Pharma A/S shares in Q4 2025, an estimated $3.08M.
Zimmer Partners first reported a position in Ascendis Pharma A/S in Q3 2024 and held it in 5 quarters.
Zimmer Partners's Ascendis Pharma A/S position peaked at $13.3M in Q4 2024.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Zimmer Partners's 13F filing for Q4 2025, filed 17 Feb 2026.